← Human Trials & Peer-Reviewed Studies
Two years of treatment with recombinant human growth hormone increases bone mineral density in men with idiopathic osteoporosis.
Plain-language guide to PMID 12414848 (2002): randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 29 men, osteoporosis and bone density.
Key Facts
- PMID
- 12414848
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2002
- Study type
- Randomized Controlled Trial
- Authors
- Gillberg P et al. (5 authors)
- DOI
- 10.1210/jc.2002-020231
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the context of osteoporosis and bone density in this randomized controlled trial publication.
The researchers have investigated the effects of GH treatment on bone turnover, bone size, bone mineral density (BMD), and bone mineral content (BMC) in 29 men, 27-62 yr old, with idiopathic osteoporosis.
Fasting morning urine and serum samples were obtained for assay of IGF-I, bone markers, and routine laboratory tests at baseline, after 1, 12, 24, and 36 months.
Who Took Part
According to the abstract, 29 men were involved.
By PubMed's age tags, the people studied were adults and middle-aged adults, men only.
How the Study Was Run
In design terms this was a randomized study.
Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
What Was Measured
Fasting morning urine and serum samples were obtained for assay of IGF-I, bone markers, and routine laboratory tests at baseline, after 1, 12, 24, and 36 months.
The subject headings attached to it are Absorptiometry, Photon, Biomarkers, Body Composition, Bone Density, Bone Remodeling, Calcitriol and Calcium.
What This Means in Plain Language
The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 29 men in people with osteoporosis and bone density.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2002 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, Osteoporosis and bone density research.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
- Osteoporosis and bone density research
- Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.